Vistagen Therapeutics (VTGN) Accounts Payables (2011 - 2026)
Vistagen Therapeutics (VTGN) posted Accounts Payables of $1.5 million for Q1 2026, up 19.92% sequentially from $1.3 million in Q4 2025, and up 135.07% YoY from $653000.0 in Q1 2025.
Vistagen Therapeutics (VTGN) Accounts Payables (2011 - 2026) Analysis & Trends
Vistagen Therapeutics has reported Accounts Payables for 14 years, with the latest figure at $1.5 million in Q1 2026.
- Quarterly Accounts Payables rose 135.07% year-over-year to $1.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.5 million (up 135.07% YoY) and the FY2026 annual result came in at $1.5 million, up 135.07% from the prior year.
- Accounts Payables grew to $1.5 million in Q1 2026 per VTGN's latest filing, from $1.3 million in the prior quarter.
- Over five years, Accounts Payables peaked at $3.0 million in Q3 2022 and troughed at $15000.0 in Q2 2022.
- A 5-year average of $1.5 million and a median of $1.5 million in 2026 frame the typical range for Accounts Payables.
- The widest YoY moves for Accounts Payables: up 88722.22% in 2022, down 99.35% in 2022.
- Over 5 years, Accounts Payables stood at $1.6 million in 2022, then advanced by 8.64% to $1.7 million in 2023, then tumbled by 40.18% to $1.0 million in 2024, then climbed by 23.2% to $1.3 million in 2025, then gained by 19.92% to $1.5 million in 2026.
- According to Business Quant data, Accounts Payables over the past three periods registered $1.5 million, $1.3 million, and $1.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | Vistagen Therapeutics | 10.49 Mn | 10.49 Mn | - | 1.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.54 Mn |
| Dec 31, 2025 | 1.28 Mn |
| Sep 30, 2025 | 1.83 Mn |
| Jun 30, 2025 | 486,000.00 |
| Mar 31, 2025 | 653,000.00 |
| Dec 31, 2024 | 1.04 Mn |
| Sep 30, 2024 | 715,000.00 |
| Jun 30, 2024 | 1.21 Mn |
| Mar 31, 2024 | 1.55 Mn |
| Dec 31, 2023 | 1.74 Mn |
| Sep 30, 2023 | 1.31 Mn |
| Jun 30, 2023 | 1.62 Mn |
| Mar 31, 2023 | 2.47 Mn |
| Dec 31, 2022 | 1.60 Mn |
| Sep 30, 2022 | 2.96 Mn |
| Jun 30, 2022 | 15,000.00 |
| Mar 31, 2022 | 2.76 Mn |
| Dec 31, 2021 | 1,800.00 |
| Sep 30, 2021 | 2.66 Mn |
| Jun 30, 2021 | 2.32 Mn |